
Radiation oncology ☢️ resident at Fondazione IRCCS San Gerardo dei Tintori 🇮🇹 @unimib.
Joined February 2023
- Tweets17
- Following97
- Followers48
- Likes65
Maria Belmonte retweeted
No Better way to start 2025
A great Pleasure to Present our paper on Management of patients with Advanced #ProstateCancer
A Report from #APCCC24 LINK TO ARTICLE👇👇👇
sciencedirect.com/science/ar…
The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) highlights significant advances in prostate cancer management while underscoring areas where high-quality evidence is still lacking. The conference gathered expert opinions on controversial clinical issues, particularly in advanced prostate cancer, offering guidance in cases where guidelines are unclear or conflicting. The report emphasizes personalized treatment approaches, considering patient-specific factors and evolving clinical data, and stresses the importance of ongoing clinical trials to fill knowledge gaps. It provides a practical framework for physicians and patients to engage in shared decision-making, especially in complex cases of high-risk localized and locally advanced prostate cancer. Our Thanks to all authors:
@Silke_Gillessen
@fabioturco92
@Prof_IanD
@drjefstathiou
Karim Fizazi
@Prof_Nick_James
Neal Shore Eric Small Matthew Smith
@ChrisSweens1
@BertrandTOMBAL
@ZilliThomas
@neerajaiims
Emmanuel S. Antonarakis Ana Aparicio Andrew J. Armstrong Diogo Assed Bastos Gerhardt Attard Karol Axcrona Mouna Ayadi Himisha Beltran
@bjartell
@PBlanchardMD
@BourlonMaite
@Albert0Briganti
Muhammad Bulbul Consuelo Buttigliero Orazio Caffo
@cdanicas
@Ecastromarcos
Heather H. Cheng Kim N. Chi Caroline S. Clarke Noel Clarke Johann S. de Bono
@mdesantis234
@nachoduranm
@EfstathiouEleni
Onyeanunam N. Ekeke Tamer I.H. El Nahas
@drlouiseemmett
@stefanofanti4
Omolara A. Fatiregun Felix Y. Feng Peter C.C. Fong
@fontev1
@Nicola_Fossati
Daniel J. George
@marty_gleave
Gwenaelle Gravis Susan Halabi Daniel Heinrich
@ProfKHerrmann
@DrMHofman
Thomas A. Hope Lisa G. Horvath Maha H.A. Hussain
@BarbaraJereczek
Robert J. Jones Anthony M. Joshua
@ravikanesvaran
Daniel Keizman
@FacsRaja
Gero Kramer
@LoebStacy
Brandon A. Mahal Fernando C. Maluf ,
@quimmateo
David Matheson, Mika P. Matikainen , Ray McDermott,
@DrRanaMcKay
Niven Mehra,
@amerseburger
@CaPsurvivorship
Michael J. Morris , Hind Mrabti, Deborah Mukherji
@declangmurphy
Vedang Murthy Shingai B.A. Mutambirwa
@DrPaulNguyen
@WilliamOhMD
@piet_ost
Joe M. O’Sullivan Anwar R. Padhani Chris Parker Darren M.C. Poon Colin C. Pritchard Danny M Rabah Dana Rathkopf Robert E. Reiter Raphaele Renard-Penna Charles J. Ryan Fred Saad Juan Pablo Sade Shahneen Sandhu Oliver A. Sartor Edward Schaeffer Howard I. Scher Nima Sharifi Iwona A. Skoneczna Howard R. Soule
@DrSpratticus
Sandy Srinivas
@cnsternberg
Hiroyoshi Suzuki Mary-Ellen Taplin Camilla Thellenberg-Karlsson Derya Tilki Levent N. Türkeri Hiroji Uemur
@DrYukselUrun
Claire L. Vale Neha Vapiwala Jochen Walz Kosj Yamoah Dingwei Ye Evan Y. Yu Almudena Zapatero
@AOmlin
Maria Belmonte retweeted
Our real-world analysis on #SBRT ⚡️ and #oligoprogressive #LungCancer 🫁 is officially published and open access!
▶️TTNT 8 months saves⏳✅
Take a look: mdpi.com/1718-7729/31/11/505
Amazing team effort @riccardo_ray @CChissotti @MariaBelmonte95 @valefacc22 @PanizzaDenis @StAr_MCM74
Maria Belmonte retweeted
🤙🏻 Excited and proud of presenting the #ABRUPT trial @ASTRO
🙏 to all 1️⃣-fraction believers who followed me in this fool and amazing project
@CChissotti @Fefe_Ferrario @Raffa_Lucchini @MariaBelmonte95 @riccardo_ray @valefacc22 @PanizzaDenis
Maria Belmonte retweeted
🎬 our paper on 1️⃣-shot⚡️RT for UIR and HR PCa is finally out on @IJROBP
👏kudos to the authors for the team effort!
#ABRUPT
@CChissotti @Fefe_Ferrario @Raffa_Lucchini @MariaBelmonte95 @riccardo_ray
@valefacc22 @PanizzaDenis
redjournal.org/article/S0360…
Maria Belmonte retweeted
🌟 The 9th edition of
TNM Classification for
Lung Cancer 🫁
1, January, 2024 〜
Maria Belmonte retweeted
Stereotactic body radiation therapy for prostate cancer after surgical treatment of prostatic obstruction: Impact on urinary morbidity @Achard_Verane @VedangMurthy @docpriyamvada ctro.science/article/S2405-6…
Maria Belmonte retweeted
💥Finally the results of our experience in managing uncomplicated painful bone metastases (BM) patients.
Pain response (CR+PR):
✔️62% at 1 month
✔️60% at 3 months.
📌A multidisciplinary approach is paramount to provide a better care to BM patients.
Maria Belmonte retweeted
Replying to @AlbertoBossial
@AlbertoBossial on the role of RT in MHSPC, discussing Stampede and Peace 1 results during #Prosca2023.
@GETUG_Unicancer
@OncoAlert @PCaParker – at Malaga, Spain
Maria Belmonte retweeted
💥 Proud to present my first manuscript on salvage SBRT for PCa late toxicity and QoL, now in @ctRO_journal 💥
Check out the POPART 🇮🇹multicentric trial ctro.science/article/S2405-6…
@StAr_MCM74 @CiroFranzese1 @valefacc22 @MartaScorsetti @PanizzaDenis @MariaBelmonte95 @Raffa_Lucchini
Throwback to Marseille #emuc2023.
It was an honour and a pleasure to share the preliminary results of ABRUPT trial, single dose of 24 Gy on prostate gland is:
✅Feasible
✅Well tolerated
A special thanks to my Professor @StAr_MCM74 and to my coworker and mentor @Raffa_Lucchini . – at Marseille, France
Maria Belmonte retweeted
Friday night with @unimib ☢️residents in Monza! 💥
What a team!🤩🔝
@SofiaBianchi93 @martina_midulla @MiriamTorrisi @Fefe_Ferrario @CChissotti @MariaBelmonte95 @airo_young
Maria Belmonte retweeted
The Lucerne Toolbox 2 to optimise axillary management for early #breastcancer : a multidisciplinary expert consensus
Just published eClinicalMedicine!
sciencedirect.com/science/ar…
@OncoAlert #OncoAlert
Maria Belmonte retweeted
What a day! Co-chair of #prostateSBRT session and interview by @Accuray #ESTRO2023 – at Vienna, Austria
Maria Belmonte retweeted
IBA Proton therapy - Power up event @labstelle Wien ✨
It was a pleasure to meet you @LMU_Muenchen Belka Claus
Maria Belmonte retweeted
Multidisciplinary approach is the key 🎯☢️💊🔪
#urooncology #iov
Maria Belmonte retweeted
36.25 Gy/5 fx linac-based prostate SBRT with 32.5 Gy urethra-sparing delivered every-other-day or once-a-week.
Minimal impact on tox and QoL regardless of OTT: 5-yr G2+ GU and GI tox-free survival ~76% and ~90%; 5-yr bRFS >90% redjournal.org/article/S0360…






























